All News

Aligning patient and insurer incentives through price transparency, lower out-of-pocket costs, and broader networks could boost ASC use and access.

The glofitamab-based regimen displayed manageable safety, with minimal high-grade CRS and infrequent low-grade ICANS, in relapsed/refractory LBCL.

Ritlecitinib significantly improves hair regrowth and reduces psychosocial burdens in patients with alopecia areata, enhancing emotional well-being over time.

Key factors influencing chronic urticaria duration highlight the importance of early identification and management in primary care settings.

As generative AI tools like ChatGPT, Gemini, and My AI gain popularity, new research highlights their growing role in youth mental health support.

Research shows how low-dose aspirin, lifestyle habits, and the Life’s Essential 8 checklist can affect cardiovascular risk in patients with type 2 diabetes.

Resmetirom showed comparable MASH resolution and fibrosis improvement in patients on GLP-1 RA or SGLT2i therapy and those on resmetirom alone.

Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.

Finerenone significantly reduced UACR in type 1 diabetes with chronic kidney disease, offering new hope for treatment.

The FDA approved daratumumab and hyaluronidase-fihj (Darzalex Faspro), offering a new treatment for high-risk smoldering multiple myeloma.

Oncology experts at PCOC 2025 discuss breakthrough therapies, AI-driven care, and evolving care delivery models shaping the future of oncology.

Explore how the WISeR Model addresses prior authorization reform, Medicare costs, and AI's role in tackling the health care affordability crisis.

The White House announced significant drug pricing cuts for GLP-1s for diabetes and obesity for Medicare and Medicaid beneficiaries and on TrumpRx.

The efficacy of immune checkpoint inhibitors was found in patients with both HIV and non–small cell lung cancer (NSCLC), though more inclusion of people with HIV is needed in future studies.

Remibrutinib shows promise in treating generalized myasthenia gravis, with ongoing trials assessing its efficacy and safety for patients.

Clinical trials show significant symptom improvement and potential for remission, with a safety profile similar to placebo.

Patients save most on outpatient surgeries at in-network sites, so Xiaoxi Zhao, PhD, emphasizes that transparency could help them make better cost choices.

Experts analyze how Trump's drug pricing policies, including Most Favored Nation (MFN) and tariffs, reshape pharma markets and impact patient costs and access.

Speakers at AMCP Nexus 2025 reviewed the oncology pipeline, highlighting expanded indications and new therapies advancing innovation, access, and value.

Ketogenic diets were linked to modest reductions in depressive symptoms, especially with ketone monitoring, while anxiety results remain unclear.

Subcutaneous therapy could be the future of non–small cell lung cancer (NSCLC) as it would decrease time needed for treatment.

Patients with diabetic macular edema (DME) using faricimab had durable results after 1 year in real-world practice.

In the phase 3 BRAVE-AA-PEDS trial, baricitinib led to significant scalp, eyelash, and eyebrow hair regrowth at 1 year in adolescents with alopecia areata.

RPM may improve patient access to care, especially those with high-risk conditions, but not without a significant cost.

Early-onset colorectal cancer (CRC) increases are linked to neuroendocrine tumor reclassification, not true adenocarcinoma growth.

In-network ambulatory surgery centers are cheapest, while out-of-network hospital outpatient departments nearly double costs, says Xiaoxi Zhao, PhD.

Confusion around how to verify work hours could leave millions unenrolled after the passing of the One Big Beautiful Bill Act.

A JAMA study found 30-day outpatient follow-up decreases hospital readmissions, especially for patients with heart failure and heart attack.